APRIL 4 DEADLINE: Khang & Khang LLP Announces Secu

IRVINE, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML ). Investors who purchased shares of the Company either (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”) are encouraged to contact the Firm prior to the April 4, 2017 lead plaintiff motion deadline.

If you purchased shares of Stemline during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com .

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint alleges that during the Class Period, Stemline made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and thus, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors severe harm.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com .

This press release may constitute Attorney Advertising in some jurisdictions.

Contact: Khang & Khang LLP Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com